American Society of Clinical Oncology (ASCO)
Non-profit
Founded in 1964, the American Society of Clinical Oncology is the world's leading professional organization for physicians and oncology professionals caring for people with cancer. Source
Actions
Media Outlet details
| Scope | National |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search ArticlesJoin us at the ASCO Gastrointestinal Cancers Symposium to navigate the path from innovation to implementation—where groundbreaking research meets real-world practice.
5K+ Total Attendees Exploring cutting-edge research and clinical best practices. 54 Countries Represented Including the U.S., Japan, Canada, China, the United Kingdom, and France. 770 Exhibitors Showcasing novel innovations and advanced technology.
ASCO Applauds House Energy and Commerce Committee Vote Advancing Prior Authorization Reform Bill; Calls for Full Floor Vote ASCO Applauds House Energy and Commerce Committee Vote Advancing Prior Authorization Reform Bill; Calls for Full Floor Vote
Alexandria, VA—July 21, 2026—Today, the House Committee on Energy and Commerce voted to advance the Improving Seniors’ Timely Access to Care Act (H.R. 3514/S. 1816), bipartisan legislation that would streamline prior authorization in Medicare Advantage. This follows passage in the House Committee on Ways and Means on July 15. The Association for Clinical Oncology (ASCO) applauds the committees for advancing the bill and urges passage on the House floor.
ASCO Commends House Appropriations Committee for Prioritizing Cancer Research in FY27 Bill ASCO Commends House Appropriations Committee for Prioritizing Cancer Research in FY27 Bill
The Association for Clinical Oncology (ASCO) applauds the House Appropriations Committee for prioritizing cancer research as it considers the fiscal year (FY) 2027 Labor, Health and Human Services, Education, and Related Agencies (LHHS) spending bill.
Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC): Results from the randomized phase 3 OptiTROP-Lung05 study. - ASCO
ASCO Breakthrough delivers novel research from the Asia-Pacific region PLUS key findings from recent major meetings, including #ASCO26. Register today.
First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer. - ASCO
ASCO Breakthrough delivers novel research from the Asia-Pacific region PLUS key findings from recent major meetings, including #ASCO26. Register today.
Leadership Development Program: Asia Pacific
ASCO's Leadership Development Program (LDP) in the Asia Pacific identifies and prepares leaders in oncology with essential skills to make a lasting impact within institutions, across the region, and throughout ASCO. The 2027-28 LDP: Asia Pacific application period opens June 1, 2026, and closes on August 17, 2026 at 11:59 PM ET. View Application “The ASCO LDP Asia Pacific was a highly formative experience in my leadership journey.